Previous 10 | Next 10 |
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatme...
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatme...
2023-03-31 11:08:09 ET Y-mAbs Therapeutics, Inc. (YMAB) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Tre...
2023-03-31 10:05:49 ET Gainers: Y-mAbs Therapeutics ( YMAB ) +43% . G Medical Innovations ( GMVD ) +41% . Palisade Bio ( PALI ) +20% . Inozyme Pharma ( INZY ) +17% . Paratek Pharmaceuticals ( PRTK ) +17% . Losers: Pyxis...
2023-03-30 17:59:02 ET Y-mAbs Therapeutics ( NASDAQ: YMAB ) has filed for a $150M mixed shelf offering. The filing does not necessarily indicate that a sale has begun or will occur in the future. The offering may include common stock, preferred stock, warrants, debt se...
2023-03-30 16:39:30 ET Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): FY GAAP EPS of -$2.19 beats by $0.46 . Revenue of $65.27M (+87.0% Y/Y) beats by $11.88M . For further details see: Y-mAbs Therapeutics GAAP EPS of -$2.19 beats by $0.46, revenue of...
Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022 DANYELZA conditional marketing authorization granted in China Management reiterates 2023 financial guidance First ever SADA Phase ...
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022, on Thursday, March 30, 2023, after the close of the U.S. financ...
Summary Last year, the FDA hit YMAB with a CRL for its neuroblastoma drug omburtamab. The company will need to do a new trial to get approval. Their restructuring will get them through mid-2024 with existing cash. For further details see: Y-mAbs Therapeutic...
New York, New York--(Newsfile Corp. - February 27, 2023) - Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit. The lawsuit on behalf of Y-mAbs investors has been commenced in the the United S...
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...